[Animal experimental and human pharmacologic studies with phase-II metabolites of triamterene].
Animal Experiments and Human Studies with the Phase-II Metabolite of Triamterene The described animal experiments as well as the pharmacological investigations in man show the diuretic efficacy of the phase-II metabolite of triamterene (CAS 396-01-0), OH-TA-ester. As demonstrated in the present investigation, a phase-II metabolite can not be considered only as an ineffective conjugation product, formed to accomplish the excretion of a foreign compound, but also it must be considered as an important factor in the therapy, if its pharmacologic efficacy has been established, moreover if as a result of disease-related alterations in the pharmacokinetics the phase-II metabolite cumulates.
Völger
K D
KD
Klinische Forschung I, Röhm Pharma GmbH, Weiterstadt.
D000328:Adult; D004232:Diuretics; D005260:Female; D005665:Furosemide / Q000494:pharmacology; D006321:Heart / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000187:drug effects; D008297:Male; D012964:Sodium / Q000652:urine; D014223:Triamterene / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000493:pharmacokinetics / Q000494:pharmacology
D004232:Diuretics; C026475:hydroxytriamterene sulfate ester; D005665:Furosemide; D012964:Sodium; D014223:Triamterene
Tierexperimentelle und humanpharmakologische Untersuchungen mit dem Phase-II-Metaboliten von Triamteren.